Body Pharm BPC-157 & TB-500
120,00 €Multi-dose pen · 32 mg · 3 ml
Repair, recovery & gut health
Shop by goal
Repair peptides
This group is studied for tissue repair — tendon, ligament, muscle and gut lining. It is also the group where the distance between confident marketing and published human evidence is widest, so the useful thing a class page can do here is set out exactly where that evidence stops.
Two compounds with very different evidence
BPC-157 is a synthetic pentadecapeptide with a large preclinical literature and no completed Phase II trial; human exposure has been limited to safety trials. Thymosin beta-4 has genuinely been through registered human trials — but for topical and ophthalmic use in dry eye and wound healing, not injection for musculoskeletal repair. Grouping them under "repair peptides" is reasonable pharmacologically and misleading if it implies a shared evidence base.
The replication problem
More than eighty per cent of published BPC-157 studies are attributable by author affiliation to a single research group at the University of Zagreb. Independent replication across separate laboratories is the normal precondition for treating preclinical findings as robust. This cuts both ways: it weakens the efficacy case and equally weakens any claim that adverse effects have been ruled out.
What TB-500 actually is
TB-500 as sold is commonly a fragment of thymosin beta-4 rather than the full-length protein used in the clinical trials. Where that is the case, trial data on the full-length molecule does not automatically describe the material in circulation, and the certificate of analysis is where the question is settled rather than the marketing copy.
Comparisons in this class
FAQ
Do repair peptides have human trial evidence?
Partially, and not for the use most readers have in mind. Thymosin beta-4 has registered trials for topical and ophthalmic indications. BPC-157 has safety trials only, with no completed Phase II.
Is TB-500 the same as thymosin beta-4?
Not necessarily — TB-500 as sold is commonly a fragment rather than the full-length protein that was trialled, so the trial data does not automatically transfer.
Why is the single research group mentioned so often?
Because it defines how much weight the BPC-157 literature can carry. Findings replicated only within one group's models are weakly established, for benefits and for safety alike.